STOCK TITAN
  1. Home
  2. News
  3. LLY

Eli Lilly & Co. - LLY STOCK NEWS

Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.

Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.

Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.

The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.

Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.

News

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

Rhea-AI Summary
Eli Lilly and Company (LLY) announced a 28% increase in revenue in Q4 2023, with a significant growth in New Products and Growth Products revenue. The company also achieved pipeline progress, FDA approvals, and completed acquisitions, issuing a 2024 guidance of $40.4 billion to $41.6 billion in revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
earnings
-
News

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announced the retirement of Johna Norton, executive vice president of Global Quality, after 34 years of service. An internal and external search is underway for her successor. Norton has made significant contributions to the company's quality standards, manufacturing processes, and team development. She has been instrumental in the successful transition of new molecules from development to manufacturing and the implementation of continuous manufacturing processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
News

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

Rhea-AI Summary
Akouos, Inc., a subsidiary of Eli Lilly and Company, announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, demonstrating hearing restoration within 30 days of AK-OTOF administration in the first participant with profound hearing loss. The study focuses on AK-OTOF gene therapy for OTOF-mediated hearing loss due to mutations in the otoferlin gene. The results will be presented at the 2024 Association for Research in Otolaryngology MidWinter Meeting. The initial participant, an 11-year-old with profound hearing loss from birth, experienced restored hearing across all tested frequencies, achieving thresholds within the normal hearing range at some frequencies. The therapy was well tolerated with no serious adverse events reported. AK-OTOF has been granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA and has received a positive opinion on orphan drug designation by the EMA Committee for Orphan Medicinal Products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
clinical trial
News

Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) is set to announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024. The company will conduct a conference call to provide detailed information to the investment community and media. The conference call will be accessible through a live webcast on Lilly's website, with a replay available afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
earnings
-
News

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) introduces LillyDirect™, a digital healthcare experience for patients in the U.S. living with obesity, migraine, and diabetes. The platform offers disease management resources, access to independent healthcare providers, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
News

Lilly to Participate in J.P. Morgan Healthcare Conference

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) will participate in the 42nd Annual J.P. Morgan Healthcare Conference, with CEO David A. Ricks joining a fireside chat on Jan. 9 at 5:15 p.m. Eastern time. A live audio webcast and replay will be available on Lilly's Investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
conferences
News

Lilly Completes Acquisition of POINT Biopharma

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) successfully completed the acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies for cancer treatment. The acquisition was completed through a tender offer and a second-step merger. Lilly acquired approximately 67.97% of POINT's outstanding shares. The acquisition marks Lilly's entry into the next-generation radioligand therapies space, with the goal of bringing new radioligand therapies to cancer patients to improve their outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
acquisition
-
News

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023

Rhea-AI Summary
Eli Lilly and Company (LLY) extends the expiration of the tender offer to acquire all shares of POINT Biopharma Global Inc. (PNT) at $12.50 per share in cash. The offer has been extended until Dec. 22, 2023, to fulfill the minimum tender condition. Approximately 22.81% of the issued and outstanding shares have been tendered as of Dec. 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
acquisition
-
News

Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) presents updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, at the 65th ASH Annual Meeting and Exposition. The data supports the potential role of pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
clinical trial
News

Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks

Rhea-AI Summary
Lilly's Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, as published in The Journal of the American Medical Association. The study showed Zepbound led to sustained weight loss compared to placebo, with a mean weight reduction of 20.9% at 36 weeks and a mean weight regain of 14.8% at 88 weeks for the placebo group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none

FAQ

What is the current stock price of Eli Lilly & Co. (LLY)?

The current stock price of Eli Lilly & Co. (LLY) is $746.2 as of November 15, 2024.

What is the market cap of Eli Lilly & Co. (LLY)?

The market cap of Eli Lilly & Co. (LLY) is approximately 713.4B.

What are Eli Lilly's core business areas?

Eli Lilly focuses on neuroscience, cardiometabolic, cancer, and immunology.

What are some of Eli Lilly's key products?

Key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes, and Taltz and Olumiant for immunology.

How did Eli Lilly perform financially in Q1 2024?

Eli Lilly reported a 26% year-over-year increase in revenue to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

What recent investments has Eli Lilly made?

Eli Lilly has invested $5.3 billion to expand its manufacturing site in Lebanon, Indiana, supporting the production of treatments for chronic diseases like obesity and type 2 diabetes.

Who is the new Executive Vice President of Global Quality at Eli Lilly?

Melissa Seymour has been appointed as the new Executive Vice President of Global Quality, effective July 22, 2024.

What are some recent clinical trial results shared by Eli Lilly?

Eli Lilly shared positive results from trials for insulin efsitora alfa, Verzenio, Retevmo, olomorasib, and imlunestrant, showcasing their advancements in treatments for diabetes and cancer.

In how many countries does Eli Lilly operate?

Eli Lilly operates in 18 countries and its products are sold in approximately 125 countries.

What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?

The investment will enhance production capacity for essential treatments like Zepbound and Mounjaro, aiming to meet the growing demand for these medicines.

What is the focus of Eli Lilly's ongoing research and development?

Eli Lilly's R&D focuses on innovative solutions for diabetes care, obesity, Alzheimer's disease, immune disorders, and cancer.

What are some common side effects of Eli Lilly's product Mounjaro?

Common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

Stock LLY logo
Eli Lilly & Co.

NYSE:LLY

LLY Rankings

#12 Ranked by Market Cap
#1941 Ranked by Dividends

LLY Stock Data

713.43B
950.41M
0.15%
83.46%
0.64%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
INDIANAPOLIS